Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Pacific Palisades, California Clinical Trials

A listing of Pacific Palisades, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (968) clinical trials

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

Although regorafenib was approved for use in patients who had progressive GIST despite imatinib and/or sunitinib on the basis of phase II and phase III data, it has not been examined in a systematic fashion in patients with other forms of sarcoma. Given the activity of sorafenib, sunitinib and pazopanib ...

Phase

1.28 miles

Learn More »

The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.  

Phase

1.28 miles

Learn More »

FPA150 in Patients With Advanced Solid Tumors

This is a Phase 1a/1b open-label, multicenter study to evaluate the dosing, safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of FPA150 as monotherapy and in combination with pembrolizumab, an anti-PD1 antibody, in patients with advanced solid tumors. This study includes a Phase 1a FPA150 Monotherapy Dose Escalation, Phase 1a Monotherapy ...

Phase N/A

1.28 miles

Learn More »

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma

The investigators have recently demonstrated that argininosuccinate synthase 1 (ASS1) expression is silenced in 88% of all sarcomas (n=708), and that this loss is associated with a decreased overall survival. Using the extracellular arginine depleting enzyme PEGylated arginine deiminase (ADI-PEG20), an extracellular arginine depleting enzyme, the investigators demonstrated ADI-PEG20 induces ...

Phase

1.28 miles

Learn More »

CBT-1 in Combination With Doxorubicin in Patients With Metastatic Unresectable Sarcomas Who Previously Progressed on Doxorubicin

This study evaluates the combination of CBT-1 and doxorubicin for the treatment of metastatic, unresectable sarcoma in patients who have progressed after treatment with 150mg/m2 or less of doxorubicin. Participants will receive CBT-1 on days 1-7 of each 21-day cycle, as well as doxorubicin on days 5 and 6.

Phase

1.28 miles

Learn More »

Daily Oral Regorafenib for Chemotherapy-Refractory Metastatic and Locally Advanced Angiosarcoma

PRIMARY OBJECTIVES: I. To define the progression-free survival (PFS) at 4 months with daily oral regorafenib (160 mg) in previously treated locally advanced/metastatic angiosarcoma patients SECONDARY OBJECTIVES: I. Progression-free rate at 3 and 6 months. II. Progression-free survival. III. Overall survival (up to 5 years). IV. Response rate (by Response ...

Phase

1.41 miles

Learn More »

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed. During the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based upon the following cancer diagnosis: Non-small cell ...

Phase

1.41 miles

Learn More »

Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma

This is a Phase 1 open-label study to study the safety and activity of aldoxorubicin with ifosfamide/mesna in subjects with metastatic, advanced, unresectable soft tissue sarcoma.

Phase

1.41 miles

Learn More »

BAY 1217389 is a potent and highly selective inhibitor of monopolar spindle 1 (MPS1) kinase activity. Human MPS1 is a serine threonine kinase, which functions as a core component of the spindle-assembly checkpoint (SAC), a key surveillance mechanism that monitors the attachment of spindle microtubules to the kinetochores of the ...

Phase

1.41 miles

Learn More »

Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Patients With Unresectable or Metastatic Cancer

Primary objectives: To evaluate the safety and tolerability of apatinib with nivolumab in patients with unresectable or metastatic cancer To assess efficacy by objective response rate (ORR), best overall response (BOR), time to response (TTR), and duration of response (DoR) per RECIST v1.1 and/or iRECIST To assess disease control rate ...

Phase

1.41 miles

Learn More »